

BILL SUMMARY
1st Session of the 59th Legislature

Bill No.:	HB2748
Version:	Introduced
Request Number:	5886
Author:	Miller
Date:	3/7/2023
Impact:	OMES-EGID plans: minimal impact to premium rates

Research Analysis

HB 2748, as introduced, prohibits step therapy requirements for certain prescription drugs to treat advanced metastatic cancer and associated conditions. The measure outlines prerequisites a health benefit plan may not require prior to covering such drugs.

Prepared By: Matthew Brenchley

Fiscal Analysis

As introduced, HB 2748 prohibits step therapy requirements for certain prescription drugs to treat advanced metastatic cancer and associated conditions. Officials at OMES anticipate that this measure would result in a minimal increase to insurance premium rates for HealthChoice plans. OMES are currently awaiting the results of an outside consultation on the estimated fiscal impact of this measure.

Prepared By: Zachary Penrod, House Fiscal Staff

Other Considerations

None.